CVS
A little selling, a lot of context
Sumitomo Mitsui Trust Group shaved 3.1% off its CVS position in the fourth quarter, which sounds dramatic until you see the actual math: it still held 2.87 million shares worth about $227.6 million. In other words, this wasn’t a “we’re out” move. It was more like trimming the hedge, not bulldozing the yard.
The real headline: CVS is still doing the thing
While the stake-cut makes the headline, CVS itself had a sturdier story underneath. The company beat Q4 expectations, posting EPS of $1.09 versus $1.00 expected and revenue of $105.69 billion versus $103.67 billion. That’s the kind of beat that doesn’t exactly send confetti into the air, but it does help calm nerves.
Guidance that says, “steady as she goes”
CVS also set FY2026 EPS guidance of $5.94 to $6.14, which lands roughly where Wall Street already was. Translation: no giant victory lap, but also no ominous eyebrow raise. When a health-care giant is basically telling you the year ahead is in line, investors tend to file that under “fine, I guess we’ll take it.”
Why you should care
There are two ways to read this story:
- A big institutional holder trimmed exposure, which can look like softening conviction.
- The company just delivered a better-than-expected quarter and decent guidance, which is usually the part long-term investors care more about.
So yes, CVS is getting a little haircut. But the business itself is still walking out of the salon looking pretty okay. Big picture: the stock’s next move probably depends more on whether the earnings momentum sticks than on one fund’s portfolio housekeeping.